Sano Genetics has been awarded a grant from Innovate UK to explore the psychological impact on people at risk of motor neurone disease (MND) – also known as amyotrophic la
UK startup Sano Genetics has raised $11 million in first-round financing to develop its go-between service, which aims to overcome one of the big challenges in clinical research by connecti
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh